BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beuselinck B, Vano Y, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib: Prognostic impact of CRP on metastatic RCC outcomes. BJU Int 2014;114:81-9. [DOI: 10.1111/bju.12494] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Tachibana H, Nemoto Y, Ishihara H, Fukuda H, Yoshida K, Iizuka J, Hashimoto Y, Kondo T, Tanabe K, Takagi T. Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2021:S1558-7673(21)00196-8. [PMID: 34772629 DOI: 10.1016/j.clgc.2021.10.005] [Reference Citation Analysis]
2 Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol 2020;25:135-44. [DOI: 10.1007/s10147-019-01528-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
3 Shinohara N, Abe T. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. Int J Urol 2015;22:888-97. [DOI: 10.1111/iju.12858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
4 Okita K, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Fujita N, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Kawaguchi T, Masumori N, Kitamura H, Ohyama C. Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer 2019;17:e440-6. [DOI: 10.1016/j.clgc.2019.01.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
5 Wang Z, Peng S, Wang A, Xie H, Guo L, Jiang N, Niu Y. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis. Clin Chim Acta 2017;475:178-87. [PMID: 29080691 DOI: 10.1016/j.cca.2017.10.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
6 Gan CL, Dudani S, Heng DYC. Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future. Cancer J 2020;26:365-75. [PMID: 32947304 DOI: 10.1097/PPO.0000000000000468] [Reference Citation Analysis]
7 Peng D, He Z, Li X, Tang Q, Zhang L, Yang K, Yu X, Zhang C, Zhou L. Prognostic Value of Inflammatory and Nutritional Scores in Renal Cell Carcinoma After Nephrectomy. Clinical Genitourinary Cancer 2017;15:582-90. [DOI: 10.1016/j.clgc.2017.04.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
8 Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, Joniau S, Oyen R, De Wever L, Strijbos M, Paridaens R, Schöffski P. Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis. Clinical Genitourinary Cancer 2014;12:e205-14. [DOI: 10.1016/j.clgc.2014.04.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
9 Jiang G, Chen S, Chen M. Exploration of IMDC model in patients with metastatic renal cell carcinoma using targeted agents: a meta-analysis. Int Braz J Urol 2020;46:328-40. [PMID: 31961626 DOI: 10.1590/S1677-5538.IBJU.2019.0423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Tamura K, Osawa T, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Sugimoto M, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Komiyama M, Tanaka K, Yokomizo A, Kohei N, Shinohara N, Miyake H; Japanese Urological Oncology Group. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. Jpn J Clin Oncol 2021;51:810-8. [PMID: 33479762 DOI: 10.1093/jjco/hyaa264] [Reference Citation Analysis]
11 Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, Poncelet R, Bechter O, Albersen M, Roussel E, Baldewijns M, Tack J, Spriet I. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol 2020;76:1273-80. [PMID: 32474662 DOI: 10.1007/s00228-020-02902-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Haaker L, Tryssesoone L, Renders I, Verbiest A, Lerut E, Baldewijns M, Bourgain C, Roussel E, Van den Bulck H, Wynendaele W, Laguerre B, Rioux-Leclercq N, Oudard S, Laenen A, Debruyne PR, Albersen M, Beuselinck B. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urol Oncol 2020;38:686.e1-9. [PMID: 32430250 DOI: 10.1016/j.urolonc.2020.04.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Semeniuk-Wojtaś A, Lubas A, Stec R, Syryło T, Niemczyk S, Szczylik C. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis. Clin Genitourin Cancer 2018;16:e685-93. [PMID: 29454639 DOI: 10.1016/j.clgc.2018.01.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
14 Graham J, Dudani S, Heng DYC. Prognostication in Kidney Cancer: Recent Advances and Future Directions. J Clin Oncol. 2018;JCO2018790147. [PMID: 30372388 DOI: 10.1200/jco.2018.79.0147] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
15 Teishima J, Kobatake K, Shinmei S, Inoue S, Hayashi T, Ohara S, Mita K, Hasegawa Y, Maruyama S, Kajiwara M, Shigeta M, Mochizuki H, Moriyama H, Fujiwara S, Matsubara A. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urologic Oncology: Seminars and Original Investigations 2017;35:662.e1-7. [DOI: 10.1016/j.urolonc.2017.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
16 Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, Dumez H, Clement PM, Wildiers H, Schöffski P, Roussel E, Kinget L, Albersen M, Beuselinck B. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol 2021;:1-8. [PMID: 34711121 DOI: 10.1080/0284186X.2021.1989720] [Reference Citation Analysis]
17 Kohli M, Tan W, Vire B, Liaud P, Blairvacq M, Berthier F, Rouison D, Garnier G, Payen L, Cousin T, Joubert D, Prieur A. Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2021;13:375. [PMID: 33498444 DOI: 10.3390/cancers13030375] [Reference Citation Analysis]
18 Fujita T, Tabata KI, Ishii D, Matsumoto K, Yoshida K, Iwamura M. Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib. Mol Clin Oncol 2017;6:691-6. [PMID: 28529744 DOI: 10.3892/mco.2017.1201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2017;22:1081-6. [PMID: 28733795 DOI: 10.1007/s10147-017-1166-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
20 Coinu A, Petrelli F, Barni S. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents. Expert Review of Anticancer Therapy 2015;16:33-43. [DOI: 10.1586/14737140.2016.1109454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Rausch S, Kruck S, Walter K, Stenzl A, Bedke J. Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival. Int J Urol 2016;23:916-21. [PMID: 27520319 DOI: 10.1111/iju.13171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
22 Chrom P, Stec R, Bodnar L, Szczylik C. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. Cancer Res Treat 2018;50:103-10. [PMID: 28253564 DOI: 10.4143/crt.2017.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
23 Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Target Oncol 2019;14:453-63. [PMID: 31359231 DOI: 10.1007/s11523-019-00660-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
24 Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy. Urologic Oncology: Seminars and Original Investigations 2020;38:6.e9-6.e16. [DOI: 10.1016/j.urolonc.2019.07.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol 2019;26:31-47. [PMID: 30253448 DOI: 10.1111/iju.13801] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
26 Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Okumi M, Ishida H, Tanabe K. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2020;38:526-32. [DOI: 10.1016/j.urolonc.2019.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
27 Miyake H, Harada K, Ozono S, Fujisawa M. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Clinical Genitourinary Cancer 2017;15:122-8. [DOI: 10.1016/j.clgc.2016.06.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
28 Zhou L, Cai X, Liu Q, Jian ZY, Li H, Wang KJ. Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis. Sci Rep 2015;5:12733. [PMID: 26235332 DOI: 10.1038/srep12733] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
29 Sacré A, Barthélémy P, Korenbaum C, Burgy M, Wolter P, Dumez H, Lerut E, Loyson T, Joniau S, Oyen R, Debruyne PR, Schöffski P, Beuselinck B. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Acta Oncologica 2016;55:329-40. [DOI: 10.3109/0284186x.2015.1099731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Tamura K, Ando R, Takahara K, Ito T, Kanao K, Yasui T, Shiroki R, Miyake H. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy. Urol Oncol 2021;39:78.e1-8. [PMID: 32958444 DOI: 10.1016/j.urolonc.2020.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Cho DS, Kim SI, Choo SH, Jang SH, Ahn HS, Kim SJ. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma. Scand J Urol 2016;50:186-91. [PMID: 26878156 DOI: 10.3109/21681805.2015.1136677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
32 Pilskog M, Beisland C, Akslen LA, Bostad L, Haug Å, Heinrich D, Hjelle KM, Straume O. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. BMC Urol 2017;17:74. [PMID: 28859644 DOI: 10.1186/s12894-017-0267-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K. Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. Clin Genitourin Cancer 2017;15:495-501. [PMID: 28363437 DOI: 10.1016/j.clgc.2017.01.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
34 Roussel E, Kinget L, Verbiest A, Debruyne PR, Baldewijns M, Van Poppel H, Albersen M, Beuselinck B. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Urol Oncol 2021;39:239.e17-25. [PMID: 33485762 DOI: 10.1016/j.urolonc.2020.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Mizuno R, Kimura G, Fukasawa S, Ueda T, Kondo T, Hara H, Shoji S, Kanao K, Nakazawa H, Tanabe K, Horie S, Oya M; Tokyo Metropolitan Study Group. Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma. Cancer Sci 2017;108:1858-63. [PMID: 28699300 DOI: 10.1111/cas.13320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
36 Dillekås H, Straume O. The link between wound healing and escape from tumor dormancy. Surg Oncol 2019;28:50-6. [PMID: 30851911 DOI: 10.1016/j.suronc.2018.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. BMC Cancer 2019;19:17. [PMID: 30616534 DOI: 10.1186/s12885-018-5224-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Dielmann A, Letsch A, Nonnenmacher A, Miller K, Keilholz U, Busse A. Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients. Cancer Immunol Immunother 2016;65:181-92. [PMID: 26753694 DOI: 10.1007/s00262-015-1786-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
39 Zhang X, Wang C, Li H, Niu X, Liu X, Pei D, Guo X, Xu X, Li Y. miR-338-3p inhibits the invasion of renal cell carcinoma by downregulation of ALK5. Oncotarget 2017;8:64106-13. [PMID: 28969055 DOI: 10.18632/oncotarget.19329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
40 Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. Clinical Genitourinary Cancer 2017;15:598-604. [DOI: 10.1016/j.clgc.2017.04.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
41 Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, Shinmei S, Shoji K, Inoue S, Hayashi T, Inoue Y, Ohara S, Mita K, Matsubara A. The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma. BJU Int 2016;117:E67-74. [DOI: 10.1111/bju.13260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
42 Roussel E, Verbiest A, Milenkovic U, Van Cleynenbreugel B, Van Poppel H, Joniau S, Beuselinck B, Albersen M. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scandinavian Journal of Urology 2020;54:493-9. [DOI: 10.1080/21681805.2020.1814858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol 2014;31:978. [PMID: 24793747 DOI: 10.1007/s12032-014-0978-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
44 Ralla B, Busch J, Flörcken A, Westermann J, Zhao Z, Kilic E, Weickmann S, Jung M, Fendler A, Jung K. miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Cancers (Basel) 2018;10:E321. [PMID: 30201928 DOI: 10.3390/cancers10090321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
45 Winer AG, Motzer RJ, Hakimi AA. Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. Urol Clin North Am 2016;43:95-104. [PMID: 26614032 DOI: 10.1016/j.ucl.2015.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
46 Van Keerberghen CA, Jean-Baptiste J, Wolter P, Zucman-Rossi J, Schöffski P, Beuselinck B. Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer 2015;13:e407-10. [PMID: 26026260 DOI: 10.1016/j.clgc.2015.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Xu S, Song J, Zhang ZH, Fu L, Gao L, Xie DD, Yu DX, Xu DX, Sun GP. The Vitamin D status is associated with serum C-reactive protein and adhesion molecules in patients with renal cell carcinoma. Sci Rep 2019;9:16719. [PMID: 31723229 DOI: 10.1038/s41598-019-53395-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Minardi D, Quaresima L, Santoni M, Bianconi M, Scartozzi M, Cascinu S, Muzzonigro G. Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature. Curr Urol Rep 2015;16:3. [PMID: 25627021 DOI: 10.1007/s11934-014-0478-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
49 Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, Scotté F, Elaidi R. Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. PLoS One 2018;13:e0195042. [PMID: 29624591 DOI: 10.1371/journal.pone.0195042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
50 Ishihara H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, Tanabe K. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Target Oncol 2018;13:745-55. [PMID: 30328067 DOI: 10.1007/s11523-018-0600-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
51 Zhang GM, Zhu Y, Gu WJ, Zhang HL, Shi GH, Ye DW. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. Int J Clin Oncol 2016;21:373-8. [PMID: 26335242 DOI: 10.1007/s10147-015-0894-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
52 Naito S, Ichiyanagi O, Ito H, Kabasawa T, Kanno H, Narisawa T, Fukuhara H, Yagi M, Kurota Y, Yamagishi A, Sakurai T, Nishida H, Kawazoe H, Yamanobe T, Kato T, Makhov P, Kolenko VM, Yamakawa M, Tsuchiya N. Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma. Oncol Lett 2019;17:3910-8. [PMID: 30881508 DOI: 10.3892/ol.2019.10033] [Reference Citation Analysis]
53 Miyazaki A, Miyake H, Harada KI, Inoue TA, Fujisawa M. Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. Mol Clin Oncol 2015;3:601-6. [PMID: 26137274 DOI: 10.3892/mco.2015.487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
54 Stenman M, Laurell A, Lindskog M. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol. 2014;31:841. [PMID: 24477648 DOI: 10.1007/s12032-014-0841-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]